Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ADMA Biologics ( (ADMA) ) just unveiled an announcement.
ADMA Biologics, a U.S.-based commercial biopharmaceutical company specializing in plasma-derived biologics for immunodeficient and infection-risk patients, manufactures three FDA-approved immune globulin products and operates its own plasma collection and fractionation facilities. The company also pursues pipeline development with SG-001, reinforcing its focus on targeted immune therapies.
On March 2, 2026, ADMA announced a 2026 capital return initiative targeting about $200 million, anchored by a $125 million accelerated share repurchase agreement with JPMorgan funded via its revolving credit facility. Executed under a broader $500 million buyback authorization, the deal will initially deliver roughly 6.4 million shares and lift total repurchases since May 2025 to about $160 million, signaling management’s view that the stock is undervalued and underscoring confidence in cash flow, growth prospects and disciplined capital allocation for shareholders.
The most recent analyst rating on (ADMA) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.
Spark’s Take on ADMA Stock
According to Spark, TipRanks’ AI Analyst, ADMA is a Outperform.
The score is driven primarily by strong fundamental improvement (revenue/margin scale-up and lower leverage) and upbeat guidance/margin expansion drivers from the latest call. This is tempered by weakening 2025 cash conversion and clearly bearish technical signals with the stock below major moving averages and negative MACD.
To see Spark’s full report on ADMA stock, click here.
More about ADMA Biologics
ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty plasma-derived biologics. Its FDA-approved products, including ASCENIV, BIVIGAM and NABI-HB, target immunodeficient patients and others at risk for certain infectious diseases, supported by its own plasma collection network and Boca Raton manufacturing facility.
The company also holds numerous U.S. and foreign patents related to its immune globulin portfolio and is advancing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia. ADMA’s mission centers on serving niche patient populations with immune-compromising conditions, leveraging vertically integrated operations from source plasma collection to finished biologic therapies.
Average Trading Volume: 2,431,262
Technical Sentiment Signal: Sell
Current Market Cap: $3.71B
Find detailed analytics on ADMA stock on TipRanks’ Stock Analysis page.